Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 8
GLP-1 Use After Bariatric Surgery
A retrospective cohort found no statistically significant weight-loss difference after bariatric surgery when GLP-1 medicines were started within a year.
Are healthcare systems ready for GLP-1s?
GLP-1 readiness requires continuity, transparent access rules and realistic expectations, not only an effective prescription.
HISTORI Semaglutide Record: What We Know
A PubMed record describes a semaglutide trial in schizophrenia, prediabetes, and obesity, but currently supplies no abstract or outcome data.
MASH combination therapy: review insights
A 2026 review explains why MASH combination therapy is being explored, while leaving major questions unresolved.
MASH eligibility tests: study findings
A multicentre cohort found that proposed non-invasive MASH eligibility criteria classified many patients differently.
Retatrutide and gut-health claims
A podcast discussion can raise useful questions, but phase 2 retatrutide evidence does not make it an approved general tool for gut health.
STEP UP semaglutide muscle findings
A small STEP UP MRI subgroup found lower thigh fat infiltration and lower measured muscle volume, with sit-to-stand repetitions preserved.
BPC-157 vs TB-500 for injury recovery
BPC-157 has more injury-specific animal research than TB-500, but neither has solid human evidence for faster recovery.
Ipamorelin vs CJC-1295: GH-axis stack
Ipamorelin and CJC-1295 act on different GH pathways, but no human trial has shown that combining them improves clinical outcomes.
The science behind nose-to-brain peptides
Semax, Selank and oxytocin sprays can reach the brain via the olfactory nerve, but not through any special breathing or injection trick.
What 49 Online GLP-1 Prescribers Required
A secret-shopper study found rapid access to GLP-1 prescriptions across 49 US websites, often without direct clinician-patient communication.
Oral Semaglutide and Cognitive Decline Risk
A small elderly-cohort study links oral semaglutide to less cognitive impairment than DPP-4 inhibitors, but a large Alzheimer's trial found no benefit.